Fibronectin and procollagen 3 levels in bronchoalveolar lavage of asbestos-exposed human subjects and sheep.

To evaluate the potential interest of levels of fibronectin and procollagen 3 in bronchoalveolar lavage fluid as markers of fibrogenic activity, we characterized the time course of changes in fibronectin and procollagen 3 levels in the tracheal lobe of sheep exposed to nonfibrogenic and fibrogenic materials. We correlated these observations with those of bronchoalveolar lavage in long-term asbestos workers in various stages of disease activity. Following studies before exposure, the tracheal lobe of three groups of 24 sheep were exposed once to 100 ml of phosphate-buffered saline solution (PBS), to 100 mg of latex beads in 100 ml of PBS, or to 100 mg of chrysotile fibers in 100 ml of PBS. Bronchoalveolar lavages were obtained at 0, 1, 2, 4, 8, and 12 months after exposure, and four or five sheep per group were killed after each lavage for histopathologic analysis. Fibronectin in bronchoalveolar lavage fluid increased significantly only in the asbestos-exposed sheep to values two to three times above controls or latex-exposed sheep and remained elevated during the 12 months of the study. Levels of procollagen 3 in bronchoalveolar lavage fluid were increased significantly only during the first two months following exposure in the asbestos-exposed sheep only. In the asbestos workers without disease, levels of fibronectin and procollagen 3 in bronchoalveolar lavage fluid were comparable to controls, but these levels were significantly elevated in those with asbestos-associated alveolitis or asbestosis. This study documents that the measurement of levels of fibronectin and procollagen 3 in bronchoalveolar lavage fluid assesses fibrogenic activity of alveolitis and should be useful to predict its progression in a fibrotic process. In asbestos workers the potential use of these markers is primarily related to early detection of asbestos-induced pulmonary injury.

[1]  G. Laurent,et al.  Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis. , 1984, Collagen and related research.

[2]  E. Engvall,et al.  Binding of soluble form of fibroblast surface protein, fibronectin, to collagen , 1977, International journal of cancer.

[3]  M. Rola-Pleszczynski,et al.  Computer-based quantitative analysis of gallium-67 uptake in normal and diseased lungs. , 1983, Chest.

[4]  A. Cantin,et al.  Airway function in lifetime-nonsmoking older asbestos workers. , 1983, The American journal of medicine.

[5]  M. Rola-Pleszczynski,et al.  Sequential analysis of the bronchoalveolar milieu in conscious sheep. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.

[6]  M. Rola-Pleszczynski,et al.  Asbestos exposure enhances the release of fibroblast growth factor by sheep alveolar macrophages. , 1983, Journal of the Reticuloendothelial Society.

[7]  G. Laurent,et al.  Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance. , 1984, Thorax.

[8]  R. Bégin,et al.  Morphologic features and function of the airways in early asbestosis in the sheep model. , 1982, The American review of respiratory disease.

[9]  M. Turner-Warwick,et al.  Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens. , 1983, Thorax.

[10]  J. Savory,et al.  Manual nephelometric methods for immunochemical determination of immunoglobulins IgG, IgA, and IgM in human serum. , 1972, Clinical chemistry.

[11]  M. Rola-Pleszczynski,et al.  Rapid in vivo assessment of toxicity of respirable particles: a concise report. , 1983, Research communications in chemical pathology and pharmacology.

[12]  M. Rola-Pleszczynski,et al.  Asbestos-induced lung injury in the sheep model: the initial alveolitis. , 1983, Environmental research.

[13]  M. Rola-Pleszczynski,et al.  Clinical features to stage alveolitis in asbestos workers. , 1985, American journal of industrial medicine.

[14]  R. Crystal,et al.  Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease. , 1982, The Journal of clinical investigation.

[15]  M. Rola-Pleszczynski,et al.  Selective exposure and analysis of the sheep tracheal lobe as a model for toxicological studies of respirable particles. , 1985, Environmental research.

[16]  R. Crystal,et al.  Role of fibronectin as a growth factor for fibroblasts , 1983, The Journal of cell biology.

[17]  V Timbrell,et al.  UICC standard reference samples of asbestos , 1968, International journal of cancer.

[18]  K. Cutroneo,et al.  Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[19]  R. Crystal,et al.  Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Adelmann-Grill,et al.  Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. , 1981, Thorax.

[21]  M. Rola-Pleszczynski,et al.  Pulmonary uptake of gallium-67 in asbestos-exposed humans and sheep. , 2015, The American review of respiratory disease.

[22]  A. Cantin,et al.  Radiographic assessment of pleuropulmonary disease in asbestos workers: posteroanterior, four view films, and computed tomograms of the thorax. , 1984, British journal of industrial medicine.

[23]  R. Bégin,et al.  Flow and age dependence of airway closure and dynamic compliance. , 1975, Journal of applied physiology.

[24]  J. Foidart,et al.  Enzyme-linked immunoassay (ELISA) for connective tissue components. , 1980, Analytical biochemistry.

[25]  R. Timpl,et al.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease , 1979, European journal of clinical investigation.